Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)

NCT01905657 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

1034

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer (NSCLC)

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Docetaxel

Sponsor

Merck Sharp & Dohme LLC